Use of Selective JAK Inhibitor in ILD and Skin Tightness of Systemic Sclerosis Versus MMF

NCT06758947 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

60

Enrollment

OTHER

Sponsor class

Conditions

Interstitial Lung Disease Due to Systemic Disease (Disorder)

Interventions

DRUG: Upadacitinib 15 MG
DEVICE: Cellcept Oral Product

Sponsor

Assiut University